Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

32.14USD
26 May 2017
Change (% chg)

$-0.02 (-0.06%)
Prev Close
$32.16
Open
$32.18
Day's High
$32.29
Day's Low
$32.10
Volume
11,699,041
Avg. Vol
23,676,060
52-wk High
$37.39
52-wk Low
$29.83

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 1.00
Market Cap(Mil.): $191,397.80
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.98

Financials

  PFE Industry Sector
P/E (TTM): 26.94 14.27 17.41
EPS (TTM): 1.19 -- --
ROI: 5.28 -7.17 -5.42
ROE: 12.02 -6.63 -4.68

BRIEF-Pfizer reports 4.7 pct stake in pSivida Corp as of May 15 - SEC filing

* Pfizer Inc reports 4.7 percent stake in pSivida Corp, as of May 15, 2017 - SEC filing

May 26 2017

BRIEF-FDA committee recommends approval of Pfizer's epoetin alfa biosimilar

* FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen®/Procrit® across all indications

May 25 2017

Pfizer must face Lipitor injury lawsuits in California state court - judge

Pfizer Inc has lost a bid to remove from California state to federal court lawsuits by about 4,800 women who claim they developed diabetes as a result of taking the blockbuster anti-cholesterol drug Lipitor.

May 24 2017

BRIEF-Pfizer recommends shareholders reject below-market mini-tender offer by TRC Capital

* Pfizer recommends shareholders reject the below-market mini-tender offer by TRC Capital Corporation

May 24 2017

AstraZeneca asthma shot hits goal but diabetes drug lags rival

LONDON AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.

May 23 2017

Severe asthma drug shows AstraZeneca promise beyond cancer

LONDON, May 22 AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.

May 22 2017

CHMP backs Novartis's Zykadia for first-line use in lung cancer

ZURICH Novartis's push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

May 19 2017

CHMP backs Novartis's Zykadia for first-line use in lung cancer

ZURICH Novartis's push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

May 19 2017

CHMP backs Novartis's Zykadia for first-line use in lung cancer

ZURICH, May 19 Novartis's push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

May 19 2017

Merck KGaA TV crystals sales decline raises stakes for cancer drug

FRANKFURT Merck KGaA's sales of liquid crystals used in flat-screen TVs are now expected to decline this year, making the German company more reliant on its new cancer immunotherapy drug to fuel growth.

May 18 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.92 -0.61
Novartis AG (NOVN.S) CHF78.60 -0.50
Merck & Co., Inc. (MRK.N) $64.92 -0.12
Roche Holding Ltd. (ROG.S) CHF266.60 -0.60
Roche Holding Ltd. (RO.S) CHF267.75 +0.25
Abbott Laboratories (ABT.N) $44.71 +0.76
Bayer AG (BAYGn.DE) €116.70 -0.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.74 +0.43
AstraZeneca plc (AZN.L) 5,227.00 +18.00

Earnings vs. Estimates